Limited expression of B-cell maturation antigen in acute myeloid leukemia
Journal for ImmunoTherapy of Cancer · 2026-03 · 14 (3) · e014595
DOI: 10.1136/jitc-2025-014595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 23.03.2026. Verfasst von Yue Ran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: B-Cell Maturation Antigen, Leukemia, Myeloid, Acute. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Basic-Clinical Collaborative Innovation Project from Shanghai Immune Therapy Institute, National Natural Science Foundation of China, Explorers Program of Shanghai.
Abstract (Originalsprache)
B-cell maturation antigen (BCMA) was recently identified as a target of T-cell-directed therapy for acute myeloid leukemia (AML), based on the study reporting high BCMA abundance in AML cells using the flow cytometry anti-BCMA antibody clone 19F2 (BCMA-19F2). However, our independent investigation demonstrated limited BCMA levels in both AML patient samples and AML cell lines through the analysis of established transcriptome profiles. The low BCMA expression in AML cells was validated by flow cytometry using an alternative anti-BCMA antibody (clone REA315) and western blotting. Importantly, we unveiled that the BCMA-19F2 could bind non-specifically to AML cells via its non-antigen-binding fragment, as evidenced by the isotype control experiment and Fc receptor blocking assay. Furthermore, cytotoxicity assay confirmed that the leukemic cell lysis was minimal on the treatment of anti-BCMA CAR T cells. Our data suggest that BCMA expression is restricted in AML, and the BCMA-19F2 is unsuitable for BCMA detection in the context of AML samples. It underscores that the accurate assessment of tumor antigen is paramount for therapeutic target design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Hematology, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- National Research Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Shanghai Institute of Hematology, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China xj11913@rjh.com.cn.
- Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University, Shanghai, China.
Förderung
- Basic-Clinical Collaborative Innovation Project from Shanghai Immune Therapy Institute
- National Natural Science Foundation of China
- Explorers Program of Shanghai
Zitieren
APA
Ran, Y., Cheng, W., Yi, X., Yang, S., Zhang, W., & Xu, J. (2026). Limited expression of B-cell maturation antigen in acute myeloid leukemia. Journal for ImmunoTherapy of Cancer, 14(3), e014595. https://doi.org/10.1136/jitc-2025-014595
Vancouver
Ran Y, Cheng W, Yi X, Yang S, Zhang W, Xu J. Limited expression of B-cell maturation antigen in acute myeloid leukemia. Journal for ImmunoTherapy of Cancer. 2026;14(3):e014595. doi:10.1136/jitc-2025-014595
BibTeX
@article{Ran2026,
author = {Ran, Yue and Cheng, Wenyan and Yi, Xiao and Yang, Shuangshuang and Zhang, Wu and Xu, Jie},
title = {Limited expression of B-cell maturation antigen in acute myeloid leukemia},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {3},
pages = {e014595},
doi = {10.1136/jitc-2025-014595}
}
EUVIMED